The Australian Hunter Syndrome Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
MPS II is an inherited disorder that encompasses a wide spectrum of severity. In some people the brain may be affected in combination with physical symptoms; others may develop physical symptoms with no brain involvement. Hunter syndrome is known to be caused by an iduronate-2-sulfatase enzyme deficiency. Physical symptoms may include hearing problems, bone and joint malformation, and heart and breathing difficulties. Hunter syndrome, also called mucopolysaccharidosis II or MPS II, is a rare disease that’s passed on in families. It mainly affects boys. Their bodies can’t break down a kind of sugar that builds bones, skin, tendons, and other tissue. Those sugars build up in their cells and damage many parts of the body, including the brain. The MPS group of disorders belong to a larger group of about 50 inherited disorders collectively known as lysosomal storage disorders.
Introduction of novel therapies, robust product pipeline, rising government initiatives, and increasing awareness regarding Hunter syndrome and its available therapeutic options are expected to significantly fuel the market growth over the forecast period. While high cost of treatment hampers the market.